

UNIVERSITI PUTRA MALAYSIA

CO-PRECIPITATION OF ACETAMINOPHEN AND EUGRAGIT RL 100 USING SUPERCRITICAL ANTI-SOLVENT IN CONTROLLED DRUG DELIVERY

CHONG GUN HEAN

FK 2009 48



CO-PRECIPITATION OF ACETAMINOPHEN AND EUGRAGIT RL 100 USING SUPERCRITICAL ANTI-SOLVENT IN CONTROLLED DRUG DELIVERY

By

CHONG GUN HEAN

Thesis Submitted to the School of Graduate Studies, Universiti Putra Malaysia, in Fulfilment of the Requirements for the Degree of Doctor of Philosophy

September 2009



Abstract of thesis to the Senate of Universiti Putra Malaysia in fulfillment of the requirement for the degree of Doctor of Philosophy

CO-PRECIPITATION OF ACETAMINOPHEN AND EUGRAGIT RL 100 USING SUPERCRITICAL ANTI-SOLVENT IN CONTROLLED DRUG DELIVERY

By

CHONG GUN HEAN

September 2009

Chairman : Associate Professor Robiah Yunus, Ph.D.

Faculty : Engineering

The controlled drug release has been proven to enhance the bioavailability of a drug by maintaining the drug concentration in therapeutic level within certain period of time and lowering the risk of drugs side effects by reducing the frequency of drug administration. Among the available drug administration systems, microcapsule has provided advantages over the conventional mode, due to higher efficiency and flexibility. This microcapsule can be produced by supercritical fluids (SCF) method which currently been used in composite particles production. This application solves the limitations of conventional pharmaceutical methods for the production of active ingredient loaded micro particles. Supercritical anti-solvent (SAS) is one of the SCF methods proven to have good potential in micronization of pure component. In this technique, SCF acts as an anti-solvent for the feed solution and the precipitation occurs when these two media (SCF and feed solution) contact each other. Therefore, the general objective of this study is to widen the application of SAS in the co-



precipitation of two components namely acetaminophen in Eudragit RL 100 towards controlling the delivery of the drug.

The investigation began with the development of a mathematical model to estimate the rate of mass transfer between a solvent droplet and CO₂ during SAS process in the supercritical regime. The simulation results show that, the solvent droplet expands when the solvent is denser than CO₂, and shrinks when the CO₂ is denser than the solvent. Both of these phenomena occur in less than one second. Based on the developed mathematical model, SAS system with 490ml of precipitation vessel is designed and developed. The design work focuses on the precipitation vessel, particle collector, temperature control system, process stream and selection of spraying device. After the commissioning of the SAS completed, the system is used to determine the optimum operating conditions for co-precipitation of acetaminophen in Eudragit RL 100. The optimum conditions are determined based on the encapsulation efficiency, particle size, product recovery and loading efficiency. The optimum conditions are 110 bars, 35 °C, 1.75 ml/min feed flow rate and 35 mg/ml polymer concentration.

The repeatability and consistency of the SAS system is also determined to ensure the accuracy of the results. At least 90% consistency is achieved in the co-precipitation of acetaminophen in Eudragit RL100 as judged by the particles size. In addition, the analysis of fourier transform infra red (FTIR) and thermo gravimetric analyzer (TGA) prove that the association between the acetaminophen and Eudragit RL 100 is physical. The results also show that the SAS process do not change the chemical structure (FTIR and high performance liquid chromatography (HPLC)) and thermal

iii

stability (TGA and differential scanning calorimetry (DSC)) of acetaminophen during the process. However, the crystallinity of treated acetaminophen is marginally reduced compared to the untreated acetaminophen (x-ray diffraction (XRD)). More importantly, SAS process has successfully improved the homogenity and size of acetaminophen which is evidenced from the image of scanning electron microscope (SEM). The diffusion coefficient for the release of the processed acetaminophen is also determined by Fick's second law in this study. In is found that the diffusion coefficient is affected by the particle size and polymer concentration. The estimated diffusion coefficient has a magnitude of 10^{-14} m²/s.

In conclusion, SAS technique has been proven to be one of the promising alternative techniques for co-precipitation of two solutes in drug microcapsules production for controlled drug delivery.



Abstrak tesis yang dikemukakan kepada Senat Universiti Putra Malaysia sebagai memenuhi keperluan untuk ijazah Doktor Falsafah

PEMENDAKAN BERSAMA ACETAMINOPHEN DAN EUDRAGIT RL100 DENGAN MENGGUNAKAN ANTI-PELARUT SUPERKRITIKAL DALAM PENGAWALAN PENGHANTARAN UBAT

Oleh

CHONG GUN HEAN

September 2009

Pengerusi : Professor Madya Robiah Yunus, Ph.D.

Fakulti : Kejuruteraan

Pengawalan penghantaran ubat yang telah dibuktikan dalam peningkatan kebolehdapatan-bio ubat dengan mengekalkan kepekatan ubat dalam tahap rawatan pada satu jangka masa dan juga mengurangkan risiko kesan tidak baik daripada ubat kerana mengurangkan frekuensi pengambilan ubat. Antara sistem pengawalan yang sedia ada, mikrokapsul memberi kebaikan seperti memberi kesan yang lebih tinggi dan cara pengambilan yang lebih fleksibel berbanding dengan cara lama. Mikrokapsul ini boleh dihasilkan melalui bendalir superkritikal (SCF) yang merupakan salah satu cara digunakan pada masa sekarang untuk menghasilkan partikel komposit. Cara ini mengatasi kekurangan cara lama yang digunakan di bidang farmaseutikal untuk menghasilkan partikel mikro yang mengandungi ramuan aktif dan ia berkembang dengan pesat dalam bidang penghasilan partikel mikro. Anti-pelarut superkritikal (SAS) adalah satu cara yang telah dibuktikan kegunaannya dalam bidang pengecilan saiz komponen tulen. Dalam cara ini, SCF berfungsi



v

sebagai anti-pelarut bagi larutan suapan dan pemendakan berlaku apabila dua media ini (SCF dan larutan suapan) bertemu. Justeru, objektif umum pengajian ini adalah untuk memperluaskan kegunaan SAS yang melibatkan dua komponen seperti pemendakan-bersama acetaminophen dalam Eudragit RL 100 untuk pengawalan penghantaran ubat.

Pengajian ini bermula dengan menerbitkan satu model matematik untuk menjangka pemindahan jisim antara titisan pelarut dan CO₂ semasa proses SAS di keadaan superkritikal. Keputusan menunjukkan bahawa titisan pelarut mengembang apabila ketumpatan pelarut adalah lebih tinggi berbanding dengan CO₂, dan titisan pelarut mengecut apabila CO₂ adalah lebih tumpat daripadanya. Walau bagaimanapun, kedua-dua keadaan ini berlaku dalam jangka masa kurang daripada satu saat. Berasaskan daripada keputusan model, satu sistem SAS dengan 490 ml benjana pemendakan telah direka dan dibangun. Ia merangkumi rekaan bejana pemendakan, pengumpul partikel, sistem pengawalan suhu, penyusunan proses dan juga alat penyebaran. Keadaan optimum untuk pemendakan bersama acetaminophen dan Eudragit RL 100 ditentukan setelah sistem SAS itu telah dikenalpasti. Keadaan optimum ini ditentukan berasas daripada kecekapan pengalutan, saiz partikel, pemulihan produk dan kecekapan pengisian. Keadaan optimum yang telah ditentukan ialah:110 bar, 35 °C, 1.75 ml/min kadar suapan and 35 mg/ml kepekatan polimer.

Sistem SAS itu juga mampu mengekalkan sekurang-kurangnya 90% konsistensi dalam pemendakan-bersama acetaminophen dan Eudragit RL 100 berasaskan saiz partikel. Hubungan antara acetaminophen dan Eudragit RL 100 adalah fizikal sahaja

vi

setelah dianalisis oleh *fourier transform infra red* (FTIR) dan *thermo gravimetric analyzer* (TGA). SAP juga dikenalpasti bahawa ia tidak mengubah struktur kimia (FTIR dan *high performance liquid chromatography* (HPLC)) dan kestabilan terhadap haba (TGA dan *differential scanning calorimetry* (DSC)) acetaminophen semasa proses. Akan tetapi, tahap kristal acetaminophen (*x-ray diffraction* (XRD)) telah berkurangan berbanding dengan acetaminophen asal. Proses SAS juga mampu mengecilkan serta menyeratakan saiz acetaminophen yang dilihat bawah *scanning electron microscope* (SEM). Angkali serapan acetaminophen yang telah diproses berjaya ditentukan dengan hukum kedua Fick dalam pengajian ini. Keputusan menunjukan bahawa ia dipengaruhi oleh saiz partikel dan juga kepekatan polimer. Anggaran angkali serapan adalah dalam linkungan 10^{-14} m²/s.

Kesimpulannya, teknik SAS menunjukkan bahawa ia merupakan cara alternatif untuk pemendakan-bersama dua komponen yang bermatlamat untuk pengawalan penghantaran ubat.



ACKNOWLEDGEMENTS

I wish to express my deepest gratitude to my supervisor Assoc. Prof. Dr. Robiah Yunus for the continuous supports of my Ph.D. study and research, her patience, motivation and financial support. Her guidance helped me in all the time of research and writing of this thesis. Besides my advisor, I would like to thank the rest of my supervisory committee: Assoc. Prof. Dr. Thomas Choong Shean Yaw, Assoc. Prof. Dr. Norhafizah Abdullah and Assoc. Prof. Dr. Sergey Spotar, for their helps, encouragement and insightful comments.

My sincere thanks also go to Assoc. Prof. Dr. S. Johnson, Dr. Khamirul Amin Matori and Dr. Rosnita Talib, UPM for their suggestions and helps as well as Dr. Tinia Idaty Mohd Ghazi for offering one semester research assistant sponsorship. Also special thanks to all the staff members of Department of Chemical & Environmental Engineering, Department of Process & Food Engineering and Department of Food Science, UPM for their helps and corporation.

Grateful acknowledges are extended to all my friends, Darmadi, Azhari, Muhammad, Asri, Ali, Bala, Shashi, Amir, Khairul, Pakcik Ismail, A Hong, Sri, Rozita, Ferra, Herliati, Shanti, Mahta, Margaret, Jehan, Mai, Azian, Nassim and others for their constant support and encouragement.

I would like to thank my parents Chong He Chai and Lim Siew Luan bringing me to this world and supporting me spiritually throughout my life. My sisters: Chai Hong, Chai Ha, Chai Tuan and family members for their love and care. Last but not least, I



would like to give special thanks to special persons in my life: my wife, Cynthia Lee Chin Chin, for giving birth to our little princess, Le Xun, her love, constant encouragement, sacrifices and understanding.



I certify that an Examination Committee has met on 29 September 2009 to conduct the final examination of Chong Gun Hean on his Doctor of Philosophy thesis entitiled "Co-Precipitation of Acetaminophen and Eugragit RL 100 Using Supercritical Anti-Solvent in Controlled Drug Delivery Application" in accordance with Universiti Pertanian Malaysia (Higher Degree) Act 1980 and Universiti Pertanian Malaysia (Higher Degree) Regulations 1981. The Committee recommends that the student be awarded the relevant degree.

Members of the Examination Committee were as follows:

Luqman Chuah Abdullah, PhD

Associate Professor Faculty of Engineering Universiti Putra Malaysia (Chairman)

Russly Abdul Rahman, PhD

Professor Faculty of Food Science and Technology Universiti Putra Malaysia (Internal Examiner)

Tey Beng Ti, PhD

Associate Professor Faculty of Engineering Universiti Putra Malaysia (Internal Examiner)

Mohd. Omar Ab. Kadir, PhD

Professor/ Ir. Pusat Pengajian Teknologi Industri Universiti Sains Malaysia (External Examiner)

BUJANG KIM HUAT, PhD

Professor and Deputy Dean School of Graduate Studies Universiti Putra Malaysia

Date:

х

This thesis was submitted to the Senate of Universiti Putra Malaysia and has been accepted as fulfilment of the requirements for the degree of Doctor of Philosophy. The members of the Supervisory Committee were as follows:

Robiah Yunus, PhD

Associate Professor Faculty of Engineering Universiti Putra Malaysia (Chairman)

Thomas Choong Shean Yaw, PhD

Associate Professor/ Ir. Faculty of Engineering Universiti Putra Malaysia (Member)

Norhafizah Abdullah, PhD

Associate Professor Faculty of Engineering Universiti Putra Malaysia (Member)

Sergey Spotar, PhD

Associate Professor Faculty of Engineering University of Nottingham (Member)

HASANAH MOHD GHAZALI, PhD

Professor and Dean School of Graduate Studies Universiti Putra Malaysia

Date: 16 November 2009



DECLARATION

I declare that the thesis is my original work except for quotations and citations which have been duly acknowledged. I also declare that it has not been previously, and is not concurrently, submitted for any other degree at Universiti Putra Malaysia or at any other institution.

CHONG GUN HEAN

Date:



LIST OF TABLES

| Table | | Page |
|-------|---|-------------|
| 2.1 | Examples of Biodegradable Polymers Used In Drug Delivery (Source: Al Fourjani, 2005) | 2-2 |
| 2.2 | Examples of Non Biodegradable Polymer (Source: Al Fourjani, 2005) | 2-2 |
| 2.3 | Examples of Water Soluble Polymers (Source: Al Fourjani, 2005) | 2-4 |
| 2.4 | List of Conventional Method Used to Prepare Encapsulated Drug | 2-5 |
| 2.5 | Critical Properties Temperature, Pressure and Density of Selected Solvent (Source: Rantakylä, 2004) | 2-11 |
| 2.6 | Supercritical Fluid Precipitation Technique and Conventional Methods for Some Particles Size Distribution (Source: Rantakylä, 2004) | 2-13 |
| 2.7 | Summary of some of SAS technique | 2-22- |
| 3.1 | Thermodynamic Properties of Anti-solvent and Solvent, Pitzer Acentric Factor (ω) | 2-24 3-8 |
| 4.1 | SCF Particles Formation Process | 4-2- |
| 4.2 | Typical Allowable Stress for Plate (Sources: Sinnott, 2003) | 4-3 4-14 |
| 5.1 | Experimental Conditions Performed Using SAS System | 5-4 |
| 6.1 | Experimental Conditions Performed Using SAS System | 6-3 |
| 6.2 | Repeatability of Experimental Results for Run 1, Run 2 and Run 3 | 6-12 |



LIST OF FIGURES

| Figure 1.1 | Comparison of Drug Concentration Profiles vs. Time Using Conventional Administration Form and Controlled Drug Delivery Form (Source: Pérez de Diego, 2005) | Page 1-2 |
|---------------|---|--------------------|
| 1.2 | Flow Chart of This Study | 1-9 |
| 2.1 | Phase Diagram of CO ₂ (Source: Ribeiro Dos Santos <i>et al.</i> , 2002) | 2-9 |
| 2.2 | Selected Physicochemical Properties of Liquid, SCF and Gas (Source: Schneider, 1980) | 2-10 |
| 2.3 | RESS Particle Formation Phase Diagram (Source: Yeo & Kiran, 2005) | 2-14 |
| 2.4 | Typical RESS Schematic Diagram (Source: Fages <i>et al.</i> , 2004) | 2-14 |
| 2.5 | Schematic Diagram and Basic Operational Principle of PGSS (Source: Yeo & Kiran, 2005) | 2-16 |
| 2.6 | Typical Schematic Diagram for GAS (Source: Rantakylä, 2004) | 2-17 |
| 2.7 | Precipitation of Solid through Solvent Induced Phase Diagram Separation (Source: Yeo & Kiran, 2005) | 2-18 |
| 2.8 | Ternary Diagram Typical SCF Anti-Solvent Technique | 2-18 |
| 2.9 | Phase Diagram of CO ₂ -Acetone at 40°C Modeled by Peng- Robinsion Equation of State | 2-27 |
| 2.10 | Experimental Data for Binary System DMSO-CO ₂ and Ternary System Cefonicid-DMSO-CO ₂ in a Pressure vs. CO ₂ Molar Fraction Diagram (Source: Reverchon <i>et al.</i> , 2007) | 2-28 |
| 2.11 | Typical Ternary Diagram for System Polymer-CO ₂ -Solvent at Constant Pressure and Temperature. a) Above Mixture Critical Point, b) Below Mixture Critical Point (Source: Pérez de Diego <i>et al.</i> , 2005) | 2-29 |
| 2.12 | Effect of CO ₂ Addition to Polymer Solution (Source: Pérez de Diego, 2005) | 2-31 |
| 2.13 | Crystallization Profile at Various Volumetric Expansion Rate (Source: Müller <i>et al.</i> , 2000) | 2-35 |



| 3.1 | Changes in Droplet Size and Mechanism of Particle Formation | 3-4 |
|----------------------------|--|------------------------------|
| 3.2 | Algorithm of Calculation Procedure | 3-13 |
| 3.3 | Comparison of Toluene Droplet Evolution at 318K which Simulated in This Work (a) and Werling and Debenedetti (2000) (b) | 3-14 |
| 3.4 | Summary of Droplet Behavior at Different Pressure and Temperature | 3-15 |
| 3.5 | Evolution of CO ₂ Mole Fraction Acetone – CO ₂ System, 318K, 100 bars, Initial Radius of Droplets 50µm | 3-16 |
| 3.6 | Evolution of Acetone Droplet Radius at 318 K and at Different Pressures. Mixture Critical Pressure at this Temperature is 70 bars | 3-17 |
| 3.7 | Evolution of Acetone Droplet Radius At 318 K at High Pressures | 3-18 |
| 3.8 | Evolution of Acetone Droplet Radius at 110 bar and Different Temperatures | 3-19 |
| 3.9 | Evolution of Acetone, Ethanol and Toluene Droplets at 318K and 110 bars | 3-20 |
| 4.1 | Behavior of a Pure Fluid in the Pressure–Temperature Phase Diagram (Source: Vemavarapu <i>et al.</i> , 2005) | 4-5 |
| 4.2 | Vapor Liquid Equilibrium of Acetone and CO ₂ at Temperature 30, 35, 40, 45 and 50 °C by Peng-Robinson Equation of State | 4-6 |
| 4.3 | Mixture Critical Point of Solvents- CO ₂ at Various | 4-7 |
| 4.4 | Temperatures Coil Heat Exchanger Used in SAS Rig | 4-8 |
| 4.5 4.6 | Design Procedure (Source: Chattopadhyay, 2005) Design Parameters for Precipitation Vessel | 4-11 4-13 |
| 4.7 | Particles Collector and Membrane Holder in SAS System Designed | 4-17 |
| 4.8 4.9 4.10 4.11 | Flow Chart of SAS System Design Verification Design of Precipitation Vessel Schematic Diagram of SAS System Photo of SAS System | 4-18 4-19 4-21 4-21 |



| 5.1 | Heavily Aggregated Product Found at the Bottom of Membrane Filter Supporter. Experimental Conditions - 70 bars, 40 °C, 1.75 ml/min Feed and 35 mg/ml Polymer | 5-8 |
|------|--|------|
| 5.2 | Effects of Pressure on Particle Characteristics | 5-9 |
| 5.3 | <i>In Vitro</i> Drug Release of Treated and Processed Acetaminophen Produced at Various Pressures | 5-10 |
| 5.4 | Particles Size Distribution at Different Temperatures (110 bars, 1.75 ml/min feed, 35 mg/ml polymer) | 5-11 |
| 5.5 | SEM Image of Processed Acetaminophen at 30 °C (110 bars, 1.75 ml/min feed, 35 mg/ml polymer) | 5-12 |
| 5.6 | SEM Image of Processed Acetaminophen at 50 °C (110 bars, 1.75 ml/min feed, 35 mg/ml polymer) | 5-13 |
| 5.7 | <i>In Vitro</i> Drug Release of Microcapsules Produced at Various Temperatures (110 bars, 1.75 ml/min feed, 35 mg/ml polymer | 5-13 |
| 5.8 | Effects of Temperature on Particle Characteristics | 5-15 |
| 5.9 | CO ₂ -Acetone Phase Diagram at 110 bars and 40 °C | 5-16 |
| 5.10 | Effects of Feed Flow Rate on Particle Characteristics | 5-17 |
| 5.11 | Particles Size Distribution of Processed Acetaminophen at Various Feed Flow Rates | 5-17 |
| 5.12 | <i>In Vitro</i> Drug Release of Microcapsules produced at Various Feed Flow Rates (110 bars, 40 °C, 35 mg/ml polymer) | 5-19 |
| 5.13 | Effects of Polymer Concentration Particle Characteristics | 5-20 |
| 5.14 | Evolution of Acetone Droplet in CO ₂ at 110 bars and 40 °C. Calculations are Performed Using Fick's Law Diffusion | 5-21 |
| 5.15 | Particles Size Distribution of Processed Acetaminophen at Various Polymer Concentrations (110 bars, 1.75 ml/min feed, 40 °C) | 5-22 |
| 5.16 | <i>In Vitro</i> Drug Release of Microcapsule Produced at Various Polymer Concentrations (110 bars, 1.75 ml/min, 40 °C) | 5-23 |
| 6.1 | Chemical Structure of Acetaminophen and Eudragit RL 100 | 6-2 |
| 6.2 | SEM Image of Untreated Acetaminophen | 6-8 |
| 6.3 | SEM Image of Treated Acetaminophen | 6-9 |



| 6.4 | SEM Image of Processed Acetaminophen (Run 1) | 6-9 |
|------|--|------|
| 6.5 | SEM Image of Treated Eudragit RL 100 (110 bar, 35 °C, 1.75 ml/min feed flow rate, 35 mg/ml polymer concentration) | 6-10 |
| 6.6 | Particles Size Distribution of Microcapsule | 6-11 |
| 6.7 | In Vitro Drug Release Profile | 6-13 |
| 6.8 | Fit of Mathematical Model to Experimental Drug Release of Processed Acetaminophen for Various Particle Sizes | 6-14 |
| 6.9 | FTIR Spectra for Treated Acetaminophen (a), Untreated Acetaminophen (b), Eudragit RL 100 (c) and Processed Acetaminophen (d) | 6-15 |
| 6.10 | High Performance Liquid Chromatography Traces of Untreated, Treated and Processed Acetaminophen (Run 1) | 6-17 |
| 6.11 | Comparison Between Acetaminophen XRD Pattern, Before and After SAS Process | 6-18 |
| 6.12 | DSC Thermograms of Untreated and Treated Acetaminophen | 6-19 |
| 6.13 | XRD Pattern of Eudragit RL 100 and Processed Acetaminophen | 6-20 |
| 6.14 | TGA Diagram of Eudragit, Processed Acetaminophen and Untreated Acetaminophen | 6-22 |
| 6.15 | DSC Thermograms of Processed Acetaminophen and Eudragit RL 100 | 6-22 |





LIST OF ABBREVIATIONS

| ρ | = Density (kmol/m ³) |
|------------------|---|
| ф | = Fugacity coefficient |
| ω | = Acentric factor |
| θ | = Temperature of CO_2 (°C) |
| Ψ_{v} | = Diameter of vessel (mm) |
| Ψ | = Outside diameter of tubing (m) |
| $ ho_A$ | = Density of anti-solvent |
| μ | = Viscosity |
| σ | = Interfacial tension droplet to surrounding |
| a, b | = Parameters in Peng-Robinson equation of state |
| a_m, b_m | = Parameters in Peng-Robinson equation of state of binary mixture |
| k, l | = Binary interaction parameters |
| r | = Radial coordinate (m) |
| t | = Time (s) |
| $\overline{V_r}$ | = Apparent radial velocity (m/s) |
| v | = Molar volume (m^3 /kmol) |
| v_f | = Superficial velocity of droplet (m/s) |
| X_A | = Mole fraction of carbon dioxide |
| u_R | = Relative velocity droplet surrounding |
| d | = Initial droplet diameter |
| с | = Specific heat of water (J/Kg °C) |
| D | = Diffusion coefficient from Fick's law (m^2/s) |
| D_{ϕ} | = Thermodynamic correction diffusion coefficient (m^2/s) |



xviii

| D_l^o | = Liquid phase diffusion coefficient at infinite dilution (m^2/s) |
|-----------------|---|
| D_g^o | = Gas phase diffusion coefficient at infinite dilution (m^2/s) |
| Ν | = Mass Flux due to composition gradients (kg/m^2) |
| L | = Length of tubing (m) |
| Q | = Feed flow rate (cm^3/min) |
| A | = Surface area (m^2) |
| A_c | = Cross sectional area of capillary (m^2) |
| L_v | = Length of vessel (mm) |
| $V_{ u}$ | = Volume of vessel (ml) |
| P_i | = Design pressure (N/mm^2) |
| R_i | = Internal radius (mm) |
| S | = Allowable stress of particular material |
| Ε | = Joint efficiency |
| C_p | = A design constant |
| D_e | = Nominal plate diameter (mm) |
| N_{We} | = Weber number |
| N _{Re} | = Reynolds number |
| N_{Oh} | = Ohnesorge number |
| M_t | = Cumulative amount of drug release at time t |
| M_{∞} | = Cumulative amount of drug release at infinite time |
| Р | = Pressure (Pa) |
| Pc | = Critical pressure (Pa) |
| Ro | = Initial droplet radius (m) |
| Т | = Temperature (K) |
| T_1 | = Inlet temperature (°C) |



xix

| М | = Mass of water (kg) |
|----------------|---|
| U | = Overall heat transfer $(W/m^2.K)$ |
| T _c | = Critical temperature (K) |
| L | = Liquid phase |
| V | = Vapor phase |
| S | = Solid phase |
| F | = Fluid |
| LST | = Lower Solution Temperature |
| UST | = Upper Solution Temperature |
| SCF | = Supercritical Fluid |
| SCCO2 | =Supercritical carbon Dioxide |
| SAS | = Supercritical Anti-Solvent |
| RESS | = Rapid Expansion Supercritical Solution |
| GAS | = Gas Anti-Solvent |
| DMSO | = Dimethyl sulfoxide |
| ASES | = Aerosol Solvent Extraction System |
| PCA | = Precipitation with a Compressed Anti-solvent |
| SEDS | = Solution Enhanced Dispersion by Supercritical fluids |
| SAS-EM | = Supercritical Anti-Solvent with Enhanced Mass transfer. |



TABLE OF CONTENTS

| ABSTRACT ABSTRAK ACKNOWLEDGEMENTS APPROVAL DECLARATION LIST OF TABLES LIST OF FIGURES LIST OF ABBREVIATIONS | | Page ii v viii x xii xiii xiv xviii |
|--|--|---|
| CHAPTER | | |
| 1. INTRODU | CTION | |
| | Background | 1-1 |
| | Problem Statement | 1-4 |
| 1.3 | Objective | 1-6 |
| 1.4 | Thesis Outline | 1-6 |
| 2. LITERATU | JRE REVIEW | |
| 2.1 | Drug Controlled Release | 2-1 |
| 2.2 | Conventional Methods for Microencapsulation | 2-4 |
| | 2.2.1 Emulsification – Solvent Evaporation | 2-5 |
| | 2.2.2 Emulsification – Solvent Diffusion | 2-7 |
| | 2.2.3 Phase Separation (Coacervation) | 2-7 |
| | 2.2.4 Spray Drying | 2-8 |
| | Supercritical Fluid | 2-8 |
| 2.4 | Supercritical Fluid Precipitation Methods | 2-12 |
| | 2.4.1 Rapid Expansion Supercritical Solutions (RESS) | 2-13 |
| | 2.4.2 Particles from Gas-Saturated Solutions (PGSS) | 2-15 |
| | 2.4.3 Gas Anti-Solvent (GAS) | 2-16 |
| | 2.4.4 Supercritical Anti-Solvent (SAS) | 2-19 |
| | Overview of SAS Experiment | 2-19 |
| 2.6 | Parameters that Influence SAS Process in | 2-25 |
| | Particle Formation | |
| | 2.6.1 Thermodynamic Behavior | 2-26 |
| | 2.6.2 Effect of Supercritical Fluid on | 2-29 |
| | Solvent- Polymer Mixture | |
| | 2.6.3 Hydrodynamics of Jet Breakup | 2-31 |
| | 2.6.4 Mass Transfer | 2-33 |
| | 2.6.5 Mechanism of Particle Formation | 2-34 |
| 2.7 | Conclusion | 2-37 |



| 3. | MASS TRA | NSFER MODELING IN SUPERCRITICAL ANTI-SO | OLVENT |
|----|----------|--|--------|
| | PROCESS | | |
| | 3.1 | Introduction | 3-1 |
| | 3.2 | Mechanism of Particles Formation | 3-3 |
| | 3.3 | Model Formulation | 3-5 |
| | 3.4 | Numerical Procedure | 3-10 |
| | 3.5 | Results and Discussions | |
| | | 3.5.1. Simulation Results and Comparison | 3-14 |
| | | 3.5.2. Mass Transfer Regime | 3-15 |
| | | 3.5.3. Effect of Pressure on Droplet and Lifetime | 3-16 |
| | | 3.5.4. Effect of Temperature on Droplet and Lifetime | 3-18 |
| | | 3.5.5. Effect of Solvent on Droplet and Lifetime | 3-19 |
| | 3.6 | 6 Conclusion | 3-20 |
| 4 | DESIGN O | F LABORATORY SCALE SUPERCRITICAL ANTI | |
| т. | SOLVENT | | |
| | | Introduction | 4-1 |
| | 4.2 | Supercritical Fluid (SCF) Delivery | 4-4 |
| | | Spray Configuration | 4-9 |
| | | Precipitation Vessel | 4-10 |
| | | Particles Collection | 4-17 |
| | 4.6 | Verification and Troubleshooting of SAS System | 4-18 |
| | | Final Design of SAS Laboratory System | 4-20 |
| | | Conclusion | 4-22 |
| 5. | SUPERCRI | TICAL ANTI-SOLVENT PRECIPITATION ON | |
| | | NOPHEN IN EUDRAGIT | |
| | 5.1 | Introduction | 5-1 |
| | 5.2 | Materials and Methods | |
| | | 5.2.1 Materials | 5-2 |
| | | 5.2.2 Apparatus and Methods | 5-3 |
| | | 5.2.3 Particles Size Distribution | 5-5 |
| | | 5.2.4 Morphology of Particles | 5-5 |
| | | 5.2.5 Concentration of Acetaminophen | 5-5 |
| | | 5.2.6 In Vitro Drug Release | 5-6 |
| | | 5.2.7 Recovery of Microcapsules | 5-6 |
| | | 5.2.8 Loading Efficiency | 5-6 |
| | | 5.2.9 Encapsulation Efficiency | 5-7 |
| | 5.3 | Results and Discussions | |
| | | 5.3.1 Effects of Pressure | 5-7 |
| | | 5.3.2 Effects of Temperature | 5-11 |
| | | 5.3.3 Effects of Feed Flow | 5-15 |
| | | 5.3.4 Effects of Feed Concentration | 5-19 |
| | 5.4 | Conclusion | 5-23 |



| 6. | CHARACT | ERIZATION OF PRECIPITATION/ | | | |
|---|-----------------------------------|---|------|--|--|
| | CO-PRECIPITATION ACETAMINOPHEN IN | | | | |
| | EUDRAGI | Г RL 100 | | | |
| | 6.1 | Introduction | 6-1 | | |
| | 6.2 | Materials and Methods | | | |
| | | 6.2.1 Materials | 6-2 | | |
| | | 6.2.2 Apparatus and Methods | 6-3 | | |
| | | 6.2.3 Analytical Methods | 6-3 | | |
| | 6.3 | Results and Discussions | | | |
| | | 6.3.1 Comparison of Particle Morphology | 6-7 | | |
| | | 6.3.2 Consistency of SAS Process | 6-10 | | |
| | | 6.3.3 In Vitro Drug Release Kinetics | 6-12 | | |
| | | 6.3.4 Mathematical Modeling of the Drug Release | 6-13 | | |
| | | 6.3.5 Interaction Between Drug and Polymer | 6-14 | | |
| | | 6.3.6 Drug Degradation and Residual Solvent | 6-16 | | |
| | | 6.3.7 Crystallographic Analysis | 6-17 | | |
| | | 6.3.8 Analysis of Thermal Properties | 6-20 | | |
| | 6.4 | Conclusion | 6-23 | | |
| 7. | CONCLUS | IONS AND RECOMMENDATIONS | | | |
| | 7.1 | Conclusions | 7-1 | | |
| | 7.2 | Recommendations | 7-4 | | |
| REFERENCE R-1 APPENDIX BIODATA OF STUDENT | | | | | |
| ы | UDATA UP | | | | |

LIST OF PUBLICATIONS





CHAPTER 1

INTRODUCTION

1.1 Background

Controlled drug delivery products in the form of composite particles, using biocompatible or biodegradable polymers, have received considerable attention in the recent years. Among the potential applications of these composite particles is the protection of the sensitive therapeutically active molecules against *in vivo* degradation. It may also reduce the toxicity side effects which can occur when some highly active drugs like those used for cancer treatment are administered in the form of a solution. Besides, it helps the patient to be more comfortable by avoiding repetitive injection or reducing the use of perfusion pumps, and may also leads to improvement in favorable drug pharmacokinetics (Gref *et al.*, 1995).

The effective use of pharmacologically active substances in the chemotherapy of cancer, viral infections, and many other diseases suffers from non-specific toxicity and poor tissue specificity of drugs. These composite particles can also be used as carriers for targeting these pharmacologically active substances by the intravenous route in order to increase the active substance's effectiveness in the diseased tissue and reduce general toxicity (Verdun *et al.*, 1986).

